CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in VitiligoGlobeNewsWire • Wednesday
CDT Insider Sentiment October 2026 - The Price Discovery Vs. Value Discovery Opportunity Part ISeeking Alpha • 11/02/26
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded PeptidesGlobeNewsWire • 10/30/26
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of LaunchGlobeNewsWire • 10/27/26
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory AssetGlobeNewsWire • 10/14/26
CDT Insider Sentiment September 2026 - A Quiet Market Drawdown And Two Opposing ThoughtsSeeking Alpha • 10/05/26
CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug DiscoveryGlobeNewsWire • 09/29/26
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and VitiligoGlobeNewsWire • 09/18/26
CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental HealthGlobeNewsWire • 09/10/26
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of GrowthGlobeNewsWire • 09/01/26
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide MarketGlobeNewsWire • 08/25/26
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property ExpansionGlobeNewsWire • 08/03/26
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to SugarcaneGlobeNewsWire • 07/20/26
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form DevelopmentGlobeNewsWire • 06/26/26
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum ComputingGlobeNewsWire • 06/18/26